Pharmaceutical Lobbying Groups Stall Legislation That Aims To Prevent Companies From Delaying Introduction Of Generic Drugs To Market
Nov 18th 2007Drug InformationPharma Industry
Legislation that would prevent brand-name drug companies from paying generic drug makers to delay market entry of generic medications “has stalled in Congress in the face of major lobbying by the drug industry,” the AP/Houston Chronicle reports. The bill, sponsored by Senate Judiciary [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
